Prostate cancer (PCa) is a common cancer in men. Although current treatments effectively palliate symptoms and prolong life, the metastatic PCa remains incurable. It is important to find biomarkers and targets to improve metastatic PCa diagnosis and treatment. Here we report a novel correlation between karyopherin α4 (KPNA4) and PCa pathological stages. KPNA4 mediates the cytoplasmto-nucleus translocation of transcription factors, including nuclear factor kappa B, although its role in PCa was largely unknown. We find that knockdown of KPNA4 reduces cell migration in multiple PCa cell lines, suggesting a role of KPNA4 in PCa progression. Indeed, stable knockdown of KPNA4 significantly reduces PCa invasion and distant metastasis in mouse models. Functionally, KPNA4 alters tumor microenvironment in terms of macrophage polarization and osteoclastogenesis by modulating tumor necrosis factor (TNF)-α and -β. Further, KPNA4 is proved as a direct target of miR-708, a tumor-suppressive microRNA. We disclose the role of miR-708-KPNA4-TNF axes in PCa metastasis and KPNA4's potential as a novel biomarker for PCa metastasis.
INTRODUCTION
One hallmark of malignancy is the metastasis of cancer cells to distant organs, which may occur even after the removal of the primary tumor and years of disease-free survival. 1 Accumulating evidence indicates that the immune system plays a critical role in controlling cancer progress. 2 Tumor necrosis factor (TNF), one of the most intensively studied cytokines, plays a central role within the complicated cytokines network, as well as in the immune response. 3 Triggering TNF signaling may initiate an immunesuppressive environment, 4 which facilitates tumor progress directly and contributes to tumor cell invasion and metastasis via the activation of the nuclear factor kappa B (NF-κB) pathway. 5 Accordingly, blocking TNF-α has been demonstrated to be an effective strategy for preventing carcinogenesis. 6, 7 Recent reports revealed that TNF-α expounds the critical role of tumor-stromal cell crosstalk 8 and promotes tumor-associated microphage (TAM) infiltration support the role of TNF-α in remodeling the tumor microenvironment (TME). 9 TAMs are involved in the cancer initiation and progression via regulation of the complex interplay between the immune system and cancer cells. 10 A study conducted in 2006 revealed that deletion of TAMs in a mouse model effectively suppressed tumor growth and metastasis. 11 Moreover, in circulation, TAM-like cells were found to interact with circulating tumor cells to promote the formation of a metastatic microenvironment. 12 Specifically, coculturing of immortalized prostate epithelial cells with macrophages can induce the prostate carcinogenesis independent of any other carcinogens, 13 suggesting that macrophage infiltration is the key to inflammation during tumorigenesis. Infiltration of TAMs is accompanied by the M1 to M2 polarization induced by the TME.
14 A human specimens study revealed that M2 macrophages infiltration is associated with the release of cytokines derived from prostate cancer (PCa) cells. 15 Furthermore, accumulating reports have shown that the declining M2 to M1 ratio of macrophages is an alternative approach in the cancer treatment rather than a global deletion. 16, 17 Nevertheless, targeting TNF or TAMs may be effective at inhibiting cancer metastasis. It is more important to identify the intrinsic alterations inside the primary tumor that promote its metastasis. In the searching for such alterations, we noted that karyopherin (KPNA), a group of importins that mediate nuclear translocation of multiple transcription factors, have the potential to be the initiating factors. KPNA4 is one of the main isoforms that mediate TNF-α-induced NF-κB p50/p65 nuclear import. 18, 19 NF-κB pathway activation is evident in PCa progression, 20 and the NF-κB gene signature has been found to be associated with PCa progression. 21 KPNA4 is also required for the nuclear localization of Notch intracellular domain, as well as the activation of Notch signaling. 22 Activation of Notch signaling is associated with tumor recurrence, 23 as well as tumor initiating and growth. 24 Therefore, KPNA4 is a potential target for the cancer therapy at least through its regulation of NF-κB and Notch signaling. A link between the KPNA family and gastric angiogenesis has been demonstrated in a model of gastric mucosal endothelial cells in vitro, in which the expressions of KPNA2 and KPNA4 were associated with the production of vascular endothelial growth factor. 25 In addition, MiR-181s have been identified as negative regulators of mesenchymal transition in glioblastoma by targeting KPNA4, 26 and miR-181a regulates prostate cell migration and invasion, 27 indicating a potential link between KPNA4 and cancer metastasis. However, the role of KPNA4 in PCa progression and its detailed mechanisms of action have yet to be investigated in depth.
Furthermore, the commitment of microRNA (miRNA) dysregulation to cell transformation has been widely reported. 28 We recently confirmed a pro-apoptosis role of miR-708 in PCa via the engagement of endoplasmic reticulum stress. 29 miRNAs are important gene regulators that are responsible for the transcription and stabilization of messenger RNA (mRNA). 30 MiR-708 is a tumor-suppressive miRNA that blocks tumor initiation and metastasis by targeting CD44 31 and neuronatin. 32 It is intriguing that KPNA4 is a predicted target of miR-708. Here, our data reveal a novel signaling pathway mediated by miR-708 downregulation of KPNA4 and TNF-α, which lead to the inhibition of tumor cell invasion and 're-education' of TAMs. These findings provide a potential biomarker and therapeutic target to improve the PCa diagnosis and treatment.
RESULTS

KPNA4 expression correlates with human PCa progression positively
We observed a strong correlation between KPNA4 expression in PCa tissues and the clinical stages from early to late using immunohistochemistry-stained PCa tissue microarray slides (Figures 1a and b) , which shows that KPNA4 locates in both of the cytoplasm and nuclear of PCa cells. A The Cancer Genome Atlas data set containing 498 PCa patient samples confirmed that KPNA is positively correlated with the clinical stages and Gleason scores of PCa, and the expression of KPNA4 is greater in metastatic site (M1) than the primary tumor (M0; Figures 1c and d) . Furthermore, the KPNA4 protein levels are distinctly higher in human PCa cells, PC3, C4-2b and LNCaP cells than normal human prostate epithelial RWPE-1 cells (Figure 1e ), indicating a promalignance role of KPNA4.
KPNA4 silencing suppresses PCa cell migration Subsequently, a transient transfection using small interfering RNAs was performed to knockdown KPNA4 in PC3 cell line (Figure 2a ). It was found that the cell mobility was significantly attenuated (Figures 2b and c) after transfection. We verified similar effects of KPNA4 on migration in C4-2B and LNCaP cells ( Supplementary  Figures 1a-d) . Later, we established two stable PC3 cell lines with scrambled small hairpin RNA (scramble control) or shKPNA4 (PC3shKPNA4) using a retrovirus-mediated small hairpin RNA system. We measured lower KPNA4 levels in PC3shKPNA4 cells using western blotting with both cytoplasm and nucleus extractions (Supplementary Figure 2a) . The reduction of KPNA4 in PC3shKPNA4 cells was accompanied by significant declines in cell migration and invasion (Supplementary Figures 2b and c) . The PC3shKPNA4 cells also exhibited decrease in lamellipodia-positive cells, indicating that less F-actin activation and cytoskeleton rearrangement that is consistent with the impaired cell mobility (Figure 2d ). Importantly, KPNA4 regulated PCa cell migration without affecting proliferation (Supplementary Figure 3) . miR-708 targets KPNA4 and inhibits PCa migration Interestingly, in contrast to significantly elevated KPNA4 expressions in protein levels in malignant PCa cells, KPNA4 mRNA levels remained similar in PCa and normal prostate epithelial cells (Supplementary Figure 4a) . This finding suggests that posttranscriptional regulation may be involved in the abnormal KPNA4 protein levels in PCa cells. miRNAs are important posttranscriptional regulators that are involved in mRNA stabilization and translation. 30 Therefore, we adopted a bioinformatics approach and found an 18-nt perfect match between miR-708 and the 3′-untranslated region of KPNA4 mRNA (Figure 3a) , supporting the assertion that KPNA4 functions as a target of miR-708. In fact, the miR-708 mimic indeed downregulated and the miR-708 inhibitor upregulated the expression of KPNA4 in the PC3 cell line (Figures 3b and c) . A dual-luciferase reporter further confirmed that miR-708 was bond to the 3′-untranslated region of KPNA4 (Figure 3d ). More importantly, miR-708 level was strikingly lower in PCa cell lines than in the non-malignant control (Supplementary Figure 4b) , explaining the aberrantly high expression of KPNA4 in protein levels, but not mRNA levels in PCa cells. Consistent with the efficacy of KPNA4 small interfering RNA, transient transfection of the miR-708 mimic attenuated PC3 cell migration (Figures 3e). Furthermore, miR-708 significantly inhibits the cell migration in PC3scramble cells, but not in PC3shKPNA4 cells (Supplementary Figure 5) . These data suggest that KPNA4 is a key regulator mediating the inhibitory effect of miR-708 on cell invasion. In other words, the inhibitory effects of miR-708 on cell invasion functions through KPNA4. These data functionally support a regulation between miR-708 and KPNA4 in regulating the cell migration. This result is consistent with recent reports on the anti-tumor role of miR-708 in PCa 29 and other types of cancer. 32, 33 KPNA4 knockdown attenuates primary tumor invasion and bone metastasis The biological significance of KPNA4 in PCa cells was determined in orthotopic and skeletal metastasis models in vivo. The PC3 cells labeled with luciferase allowed us to track tumor growth and metastasis in a real-time manner; we performed the luciferase activity assays to guarantee a robust correlation between the cell number and bioluminescence signal in both PC3shKPNA4 and scramble control cells (Supplementary Figure 6) . Six weeks after orthotopic injection, the PC3shKPNA4 group exhibited considerably fewer proximal muscle invasions than the scramble control (Figures 4a-d) , which was consistent with the transwell assay in vitro. Primary tumor masses were similar in size between these two groups (Figures 4e and f) . Meanwhile, we evaluated skeletal metastasis in an intra-cardiac injection model, in which shKPNA4 or scramble control PC3 cells were inoculated into the circulatory system through the left ventricle, and we detected metastatic lesions weekly using bioluminescent imaging. Both luciferase activity (Figures 5a and b) and X-ray images (Supplementary Figure 7 ) revealed that the rates of incidence and the sizes of the metastatic lesions were significantly reduced in the hind limbs of mice inoculated with PC3shKPNA4 cells. Hematoxylin and eosin staining also demonstrated a marked reduction in the metastatic lesion size in the PC3shKPNA4 group (Figure 5c ).
Activation of NF-κB is associated with the metastatic phenotype and PCa progression to castration-resistant PCa.
21,34-37 NF-κB also acts as a key regulator in immune response through cytokine release.
38 KPNA4 may alter cytokine expression via the NF-κB activation to promote PCa progression. Indeed, PC3shKPNA4 cells exhibited reductions in TNF-α and -β in cytokine array analysis (Supplementary Figure 8a) and was verified by western blotting (Supplementary Figure 8b) . Meanwhile, NF-κB specific inhibitor (4,6-quinazolinediamine) abolished the regulatory effect of KPNA4 on TNF-α and -β expression (Supplementary Figure 8c) , indicating that KNPA4 need active NF-κB signaling to regulate TNF-α and -β expression. TNFs are the primary cytokines involved in the immune system, 3 and their activation may facilitate tumor metastasis by promoting infiltration of TAMs. 9 As expected, the infiltration of M2-polarized TAMs, CD206-positive macrophages, was significantly decreased in PC3shKPNA4 tumors compared with PC3-scrambled control tumors in the orthotopic model (Figure 5d) . Similarly, the skeletal metastatic lesions from the mice that received intra-cardiac injections of PC3shKPNA4 cells exhibited reduced M2 populations than mice receiving PC3-scrambled control cells (Figure 5e ). Hence, KPNA4 reduction in PCa cells decreases M2 TAMs in the tumor environment in vivo. KPNA4 expression in PC3 cells transfected with either (b) miR-708 mimic/negative control or (c) miR-708 inhibitor/negative control was determined by western blotting, β-actin was used as a loading control for total cell lysate. (d) HEK293T cells were co-transfected with miR-708 mimic or negative control mimic, and dual-luciferase reporter plasmid inserted with KPNA4 3′-UTR/control 3′-UTR. Firefly luciferase was detected to determine the binding between miR-708 and KPNA4 3′-UTR, renilla luciferase was used as an internal control. (e) Transwell assay was performed to determine the cell invasion of PC3 cells that were transfected with either miR-708 mimic or control mimic for 48 h.
TNF-α and -β mediates the KPNA4 induced PCa migration
We next evaluated the expression of TNF-α and -β in primary tumor masses using immunofluorescence staining and confirmed their attenuation in orthotopic PC3shKPNA4 tumors (Figures 6a  and b) . Meanwhile, we found that either recombinant TNF-α or TNF-β at low concentrations in murine primary macrophages markedly induce the expression of cytokines related to the M2-phenotype (Figure 6c ). In addition, TNF-α directly induces osteoclastogenesis via stimulation of macrophages in both receptor activator of nuclear factor kappa-B ligand-dependent and receptor activator of nuclear factor kappa-B ligandindependent manners 39, 40 and we confirmed that both TNF-α and -β were capable of promoting osteoclastogenesis in vitro ( Supplementary Figures 9a and b) . Considering that the increases in osteoclastogenesis and osteoclast activity favors PCa skeletal metastasis, 41, 42 we examined the capability of PC3shKPNA4 and PC3-scrambled control cells in inducing osteoclastogenesis and found that in comparison with PC3-scrambled control cells, conditioned medium from PC3shKPNA4 reduced osteoclast differentiation in RAW264.7 cells. More importantly, TNF-α rescued the reduction of osteoclast differentiation from PC3shKPNA4 cellconditioned medium to the same level as the conditioned medium from PC3-scrambled control cells ( Supplementary  Figures 9c and d) . Skeletal metastasis derived from PC3shKPNA4 cells demonstrate reduced osteoclast formation in vivo (Supplementary Figure 9e) . Therefore, the dysregulation of KPNA4 in advanced PCa may not only directly stimulate the cancer cell mobility, but also play a multifaceted role in regulating cytokine crosstalk between cancer cells and cells residing in the tumor environment to affect the PCa progression and skeletal metastasis. Of note, cytokines had been proved as ideal targets for cancer. 43 PCa cells may regulate the macrophages in tumor Figures 10a and b) , which further supports the idea that KPNA4 may promote the PCa progression via altering the TME. TNF promotes the cell mobility via the activation of the NF-κB pathway in cancer cells. 5 Therefore, TNF-α and -β may directly enhance the cell mobility in PCa cells. In fact, both TNF-α and -β rescued the invasive ability of PC3shKPNA4 cells in the absence and presence of macrophages according to transwell assays (Figures 6d-f) .
Collectively, we identified the novel role of KPNA4 in PCa metastasis. The dysregulation of the miR-708-KPNA4-TNF axis can facilitate the skeletal metastasis of PCa by promoting the cancer cell mobility, polarizing TAMs and inducing osteoclastogenesis (Figure 7 ).
DISCUSSION
PCa is the most frequent type of cancer based on the incidence of new cases for men in United States; it is also the second-leading cause of death among cancers. 44 Specifically, metastatic castration-resistant PCa is currently a lethal disease, and the majority of treatment approaches for this disease are only to extend the patient survival by a few months. 45 Here we have demonstrated that the inhibition of KPNA4 may effectively block the bone metastasis of PCa, including the metastatic castrationresistant PCa cell line, in a mouse model. Indeed, consistent with reports of the significance role of other KPNA members in multiple cancer types, [46] [47] [48] [49] KPNA4 is overexpressed in PCa cell lines. Importantly, our data show that its expression is strongly associated with pathological stages and Gleason scores in human PCa samples, indicating the pro-malignance role of this nuclear importer. In support of this observation, recent genomic profiling screening also demonstrated the importance of KPNA4 during the process of prostate carcinoma. 50 Our in vitro assay verified that transient knockdown of KPNA4 in PCa cell lines attenuates migration ability, which provides direct proof of KPNA4 promoting the progression of PCa. As a matter of fact, KPNA4 is a well-known importer for NF-κB nuclear localization. 18, 51 The deletion of KPNA4 inhibits the cell migration at least partially via the regulation of the NF-κB pathway. Further investigation revealed that only the protein level of KPNA4 was overexpressed in transformed prostate cell lines, but not the RNA level. This inconsistency between protein and RNA indicates that the dysregulation of KPNA4 in PCa cells is induced via a posttranscriptional pathway, which piques our interest in the miRNAs that act as important post-transcriptional regulators in various cell processes. Accumulating evidence has suggested that cancer patients have a unique signature in miRNA expression profile comparing to healthy controls. 52 Some miRNAs such as miR-708 may function as tumor suppressors. miR-708 represses metastasis of breast, 32 ovarian 33 and PCa 31 by targeting multiple genes mRNA. Our data clearly demonstrate that miR-708 is a negative regulator of KPNA4 expression in PCa. Furthermore, miR-708 was Figure 6 . TNF-α and -β mediates the KPNA4 induced prostate cancer migration. (a and b) TNF-α and -β expression was evaluated in the primary tumor tissue by immunofluorenscence staining. (c) M2-phenotype-associated cytokines of primary murine macrophages that were subjected to TNF-α or TNF-β stimulation (5 ng/ml) were determined by real-time PCR. (d) Transwell assay of PC3-shKPNA4 or scramble control cells lines in the absence or presence of U937 cells to determine the cell invasion, PC3-shKPNA4 cells were stimulated with or without recombinant TNF-α or -β cytokines (5 ng/ml). (e and f) Invasive cells were quantitated by crystal violet staining assay. *P o0.05, **P o0.01.
found to be deregulated in PCa cell lines compared with normal prostate cell lines, which explains the abnormally high expression of KPNA4 protein (but not the RNA). In addition, KPNA4 exhibits a positive correlation with the stage of malignancy in human PCa samples on both the protein and RNA levels. This result implies that KPNA4 may be no longer controlled by miR-708 in malignant cells to increase the aggressiveness, a fact that is likely due to the extremely low-expression level of miR-708 (that is, too low to affect the expression of KPNA4 in malignant prostate cells).
Bone metastasis is the primary cause of mortality in patients with advanced PCa. 53 Here we used the aggressive PCa cell line, PC3, to evaluate how KPNA4 regulates PCa progression in vivo. Consistent with the in vitro assay, we found that KPNA4 knockdown can inhibit the invasion ability of primary tumors. Importantly, the metastatic model showed that the suppression of KPNA4 significantly reduced both the incidence and size of lesions in bone. We accordingly concluded that inhibition of KPNA4 represented an effective approach to prevent skeletal metastasis. As described earlier, KPNA4 is one of the primary importers that mediate the NF-κB nuclear translocation. KPNA4 deletion might lead to an impaired activation of NF-κB-regulated pathways, including the cytokines network. Using a cytokines array, we identified that TNF-α and -β were both downregulated in PC3shKPNA4 cells. Although TNF was initially recognized as a cytotoxic factor that can induce cell apoptosis via the caspase cascade, tumor cell-produced TNF has been shown to promote malignance in multiple cancer types. [54] [55] [56] In this study, the induction of recombinant TNF-α and -β can rescue the KPNA4-deletion-induced impairment of PCa cell migration, which indicates that TNFs are the effectors of KPNA4 in PCa progression. On the other hand, TNF plays an important role in the interaction between the tumor cells and macrophages, and the generation of the TAM phenotype. 57, 58 In the PC3shKPNA4 primary tumor tissues, we detected decreased TNF-α and -β production and attenuated M2-phenotype macrophages. This finding further supports our assertion that TNF acts as a KPNA4 effector, which not only facilitates PCa cell mobility, but also promotes the generation of TAMs. In fact, TNF-α and -β can solely induce the production of M2-phenotype-related cytokines in primary mouse monocytes. Therefore, by regulating TNF production, KPNA4 can modulate the TME via M2-polarized macrophages, which abet the tumor cells to bypass the surveillance of the immune system. Nevertheless, in the TME, KPNA4 may act as a switch of the cytokine crosstalk network and also as a regulator of TNFs. Tumor mass is characterized as a chronic inflammation environment, 59 in which macrophages play a key role in the response to microenvironment signals. 60 Here, using stimulations of the conditioned medium of PC3 cell lines, we explored the expression of inflammatory cytokines and receptors of raw264.7 macrophages using a PCR array kit (Germantown, MD, USA). Differentiated gene expression analysis (shKPNA4 VS scramble) revealed that the numbers of upregulated and deregulated genes were approximately the same; the deregulated genes exhibited a much more significant fold change, which implied that PC3shKPNA4 induces a suppressed inflammatory environment. Cytokines were enriched in the TME. In particular, TNF-α plays a critical role in the inflammatory response. 61 We believe that by regulating TNF expression, KPNA4 is also capable of enhancing the inflammatory response to promote PCa progression.
Bone-resorbing osteoclasts significantly contribute to skeletal metastasis by changing the dynamics of the osteoclast-osteoblast balance. 62 Osteoclast-mediated bone resorption can facilitate PCa cell growth and survival via the release of factors such as TGF-β. 63 In turn, PCa cells can also promote the osteoclast development and function by inducing receptor activator of nuclear factor kappa-B ligand production. 64 In this study, PC3shKPNA4-derived conditioned medium impaired osteoclast formation compared with the scramble control. Furthermore, TNF-α completely rescued the reduction of osteoclast differentiation in RAW264.7 cells treated with PC3shKPNA4-conditioned medium, suggesting that TNF-α is the major mediator of KPNA4 in the regulation of osteoclastogenesis. These data support a molecular mechanism via which KPNA4-derived cytokines promote the formation of PCa metastatic lesions in the bone environment. Therefore, KPNA4 has a bi-faceted role in promoting PCa metastasis through regulating the tumor cell mobility and TME. Hence, targeting KPNA4 could be an effective strategy to inhibit PCa metastasis via invoking antimobility in primary tumors and anti-osteoclastogenesis in the bone marrow environment.
Taken together, mechanistic evidence of KPNA4 in PCa metastasis warrants the further validation in larger clinical samples; it is also necessary to evaluate the potential of KPNA4 as a biomarker for metastatic PCa diagnoses. From the perspective of treatment, the fact that KPNA4 deletion does not affect the proliferation of PCa cells suggests that a combined therapy of targeting KPNA4 paired with an anti-proliferation agent could be effective in inhibiting PCa progression and metastasis.
MATERIALS AND METHODS
Cell lines and RNAi
Human PCa cell line PC3 was purchased from American Type Culture Collection (Manassas, VA, USA). Professor Laurie McCauley (University of Michigan) provided the human PCa cell lines C4-2B and Professor Peng Lee (New York University) provided the LNCaP, as well as human prostate epithelial cell line RWPE-1. All cell lines were authenticated and verified mycoplasma free. All PCa cell lines were cultured in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 μg/ml streptomycin. RWPE-1 was cultured in keratinocyte serum-free medium supplemented with 0.05 mg/ ml bovine pituitary extract and 5 ng/ml human recombinant epidermal Figure 7 . Schematic model of miR-708/KPNA4/TNF-α and -β signaling pathway that regulates PCa microenvironment and bone metastasis. In primary prostate tumor, miR-708 decrease in the cancer cells causes abnormal high expression of KPNA4, which will subsequently increase the TNF-α and -β expression. Enrichment of TNF-α and -β in tumor microenvironment can promote both of the cancer cell mobility and M2 polarization of TAMs. On the other hand, increased TNF-α and -β can enhance the osteoclastogenesis in bone environment, and eventually accelerate prostate cancer bone metastasis.
growth factor. The cells were incubated in a 37°C, 5% (v/v) CO 2 growth chamber.
To mediate transient RNA interference, KPNA4 small interfering RNA (Invitrogen) were transfected by Lipofectamine-3000 (Invitrogen) at a final concentration of 50 nM for 48 h. To establish the stable KPNA4 knockdown cell line, a retroviral system (Phoenix helper-free retrovirus producer lines, Nolan lab, Stanford University) was applied to package the virus following a standard procedure. We next cultured PC3 cells with the retrovirus for 24 h, and the positively infected cells were selected using puromycin at 3 ng/ml for 72 h. miRNA and dual-luciferase assay
We seeded the cells in a six-well plate 24 h before the transfection. The miRNA-708 mimic or inhibitor, as well as the negative controls (Invitrogen) were transfected with Lipofectamine-3000 at a final concentration of 50 nM for 48 h. For dual-luciferase assay, the KPNA4 3′-untranslated region reporter construct or control construct (GeneCopoeia, Rockville, MD, USA) were co-transfected with the miRNA-708 mimic or control mimic into the 293 T cells that were seeded in 96-well plate (1 × 104 cells per well). After 48 h of transfection, we measured firefly and renilla luciferase activities using the Dual-Luciferase Reporter Assay System (Promega, Medison, MI, USA) according to the manufacturer's protocol.
Western blotting and quantitative PCR Total protein was extracted using a RIPA lysis buffer (Thermo Scientific, Waltham, MA, USA), and nuclear protein was isolated using an EpiQuik Nuclear Extraction Kit (Epigentek, Farmingdale, NY, USA). Equal amounts of protein were denatured in a SDS sample buffer (2% SDS, 62.5 mM Tris-base (pH 6.8), 10% glycerol, 5% β-mercaptoethanol and 0.005% bromophenol blue) and loaded into a 10% SDS-polyacrylamide gel electrophoresis gel (Invitrogen). The gel was preceded according to a standard polyvinylidene difluoride membrane transfer and visualization protocol. The anti-KPNA4 and anti-CD206 primary antibody was purchased from Novus Biologicals (Bio-Techne, Minneapolis, MN, USA). The anti-β-actin, anti-Histone H4 primary antibodies, anti-mouse, anti-rabbit and anti-goat secondary antibodies were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA), and the anti-TNF-α, anti-TNF-β and anti-α-tubulin primary antibodies were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA).
Total RNA was purified using Trizol reagent (Invitrogen). We synthesized complementary DNA using a Taqman reverse transcription kit (Applied Biosystems, Carlsbad, CA, USA). Taqman reverse transcription kit (Applied Biosystems) was applied for complementary DNA synthesis. SYBR green super mix (Applied Biosystems) was used for real-time PCR in a CFX384 Touch qPCR System (Bio-Rad, Hercules, CA, USA).
Mouse model
The male athymic nu/nu nude mice at the age of 6 week were purchased from Charles River Laboratories International, Inc. (Kinston, NY, USA). Six mice were distributed to each group by random.
The PC3shKPNA4 and scramble control cells were collected and hand resuspended in HBSS solution at 1 × 10 7 cells per ml. For the metastatic model, we conducted an intra-cardiac injection by injecting 100 μl of cell suspension (1 × 10 6 cells) into the left ventricle of the mice. 65 Bioluminescence images were obtained 24 h after injection to ensure proper circulation distribution of cells, and images were retaken weekly for 4 weeks to track metastasis using an IVIS Lumina XR system (Caliper Life Sciences, Waltham, MA, USA). For the orthotopic model, the prostates of anesthetized nude mice were exposed via proper surgery, and 20 μl of cell suspension (2 × 10 5 cells) was orthotopically injected into the prostate. 66 The primary tumor was allowed to grow for 6 weeks. Bioluminescence images were acquired weekly or biweekly for 4 or 6 weeks as indicated. After the mice were killed, the hind limbs from the intra-cardiac-injected mice and the primary tumors from the intra-prostatic-injected mice were collected for X-ray, immunochemistry and immunofluorescence imaging. The investigators were not blinded to the group allocation during the experiment.
In vitro migration assay and cytoskeleton staining A wound-healing assay was performed using 2.5 × 10 5 cells seeded into a 24-well plate. The cells were cultured with serum-reduced medium (1% fetal bovine serum). After 24 h, the wells were scraped with 200-μl tips. We recorded the wound widths immediately using a microscope and again after 48 h for C4-2B and LNCaP, and 24 h for PC3. Transwell assays were performed by seeding 5 × 10 4 cells into transwell chambers (Costar, Cambridge, MA, USA) with 5-μm-pore polycarbonate filters. The cells were cultured using serum-reduced medium (1% fetal bovine serum) for 48 h, and the cells attached to the chamber membrane were fixed in formalin and stained with 0.05% crystal violet (Invitrogen). Cells on the top of cylindrical chambers were removed using cotton swabs. Invasive cells were determined by detecting the optical density 540 in a plate reader. For cytoskeleton staining, 1 × 10 4 cells were seeded in 96-well plate, fixed with 3.7% formaldehyde for 5 min, permeabilized with 0.1% Triton X-100 and then stained with a 50 μg/ml fluorescent phalloidin conjugate (Sigma, St Louis, MO, USA) for 40 min at room temperature. Lamellipodia-positive cells were imaged microscopically.
Immunochemistry and immunofluorescence
We purchased human PCa microarray slides from US Biomax Inc. (Rockville, MD, USA). Immunochemistry staining of the KPNA4 was performed in the histology core of the New York University Medical Center (tissue microarray data have been uploaded to figshare). For immunofluorescence staining, the primary tumor was embedded in OCT compound (Sakura, Alphen aan den Rijn, The Netherlands), frozen and sectioned. Frozen sections were fixed with 10% formaldehyde for 15 min at room temperature and washed with phosphate-bufferd saline (PBS) for three times. The fixed slides were blocked in blocking buffer (PBS/5% normal serum/0.3% Triton X-100) for 1 h and incubated with anti-CD206, anti-TNF-α and anti-TNF-β primary antibodies at 1:100 dilutions at 4°C overnight. After being rinsed three times with PBS, the slides were incubated with the Alexa Fluor 488-conjugated secondary antibody (Cell Signaling Technology, Inc.) at room temperature for 2 h. The specimens were rinsed with PBS after incubation and were then mounted for microscopic examination.
Statistical analysis
An analysis of the relationship between KPNA4 levels and clinical PCa stages or Gleason scores was carried out using the nonparametric MannWhitney-Wilcoxon test. The results revealed statistically significant differences in KPNA4 expression in PCa with different Gleason scores (Kruskal-Wallis χ 2 (4) = 19.98; Po0.0005). We also examined the extent to which the TNM classification of malignant tumors scores were associated with KPNA4 expression, using the nonparametric Mann-Whitney-Wilcoxon test. Our results revealed significant differences in KPNA4 expression as a function of TNM classification of malignant tumors (Kruskal-Wallis χ 2 (2) = 18.85; P o0.0001). We used GraphPad Prism (GraphPad Software, La Jolla, CA, USA) software or Microsoft Excel (Microsoft, Redmond, WA, USA) to statistically analyze the remaining experimental outcomes. We expressed the data as means ± s.e.m.'s of at least three independent determinations. Statistical significance was determined using the unpaired t-test. Results with Po 0.05(*), 0.01(**) or 0.001(***) are considered to be statistically significant.
Study approval
All of the animal experiments were performed according to the protocols approved by the Institutional Animal Care and Use Committee (IACUC) of New York University Medical Center following the guidelines for the proper care and use of animals for research purpose.
